Trial Profile
Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-Induced Lymphopenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Umitrelimorgene autodencel (Primary) ; Autolymphocyte therapy; Granulocyte macrophage colony stimulating factor; Tetanus toxoid
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms ATTAC; ATTAC-I
- 09 Mar 2023 Status changed from active, no longer recruiting to completed.
- 16 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology